Literature DB >> 9482271

Regional membrane phospholipid alterations in Alzheimer's disease.

M R Prasad1, M A Lovell, M Yatin, H Dhillon, W R Markesbery.   

Abstract

Regional levels of membrane phospholipids [phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylcholine (PC)] were measured in the brain of Alzheimer's disease (AD) and control subjects. The levels of PE-derived and PI-derived total fatty acids were significantly decreased in the hippocampus of AD subjects. Here significant decreases were found in PE-derived stearic, oleic and arachidonic and docosahexaenoic acids, and in PI-derived oleic and arachidonic acids. In the inferior parietal lobule of AD subjects, significant decreases were found only in PE and those decreases were contributed by stearic, oleic and arachidonic acids. In the superior and middle temporal gyri and cerebellum of AD subjects, no significant decreases were found in PC-, PE- and PI-derived fatty acids. The decrease of PE and PI, which are rich in oxidizable arachidonic and docosahexaenoic acids, but not of PC, which contains lesser amounts of these fatty acids, suggests a role for oxidative stress in the increased degradation of brain phospholipids in AD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9482271     DOI: 10.1023/a:1022457605436

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  46 in total

1.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

2.  Polyphosphoinositides as a probable source of brain free fatty acids accumulated at the onset of ischemia.

Authors:  M Ikeda; S Yoshida; R Busto; M Santiso; M D Ginsberg
Journal:  J Neurochem       Date:  1986-07       Impact factor: 5.372

3.  Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients.

Authors:  J K Blusztajn; I Lopez Gonzalez-Coviella; M Logue; J H Growdon; R J Wurtman
Journal:  Brain Res       Date:  1990-12-17       Impact factor: 3.252

Review 4.  The role of alterations in membrane lipid composition in enabling physiological adaptation of organisms to their physical environment.

Authors:  J R Hazel; E E Williams
Journal:  Prog Lipid Res       Date:  1990       Impact factor: 16.195

5.  Enhanced phosphodiestric breakdown of phosphatidylinositol bisphosphate after experimental brain injury.

Authors:  M R Prasad; H S Dhillon; T Carbary; R J Dempsey; S W Scheff
Journal:  J Neurochem       Date:  1994-08       Impact factor: 5.372

6.  In vitro 31P NMR spectroscopy detects altered phospholipid metabolism in Alzheimer's disease.

Authors:  O Miatto; R G Gonzalez; F Buonanno; J H Growdon
Journal:  Can J Neurol Sci       Date:  1986-11       Impact factor: 2.104

Review 7.  New insights on mammalian phospholipase A2(s); comparison of arachidonoyl-selective and -nonselective enzymes.

Authors:  R J Mayer; L A Marshall
Journal:  FASEB J       Date:  1993-02-01       Impact factor: 5.191

8.  Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease.

Authors:  J W Pettegrew; K Panchalingam; J Moossy; J Martinez; G Rao; F Boller
Journal:  Arch Neurol       Date:  1988-10

9.  Vitamin E protects nerve cells from amyloid beta protein toxicity.

Authors:  C Behl; J Davis; G M Cole; D Schubert
Journal:  Biochem Biophys Res Commun       Date:  1992-07-31       Impact factor: 3.575

Review 10.  The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease.

Authors:  J P Blass; G E Gibson
Journal:  Rev Neurol (Paris)       Date:  1991       Impact factor: 2.607

View more
  108 in total

Review 1.  Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis.

Authors:  Norman J Haughey; Veera V R Bandaru; Mihyun Bae; Mark P Mattson
Journal:  Biochim Biophys Acta       Date:  2010-05-07

2.  Secondary ion images of the developing rat brain.

Authors:  Peter J Todd; John M McMahon; Carl A McCandlish
Journal:  J Am Soc Mass Spectrom       Date:  2004-07       Impact factor: 3.109

3.  A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease.

Authors:  Walter J Lukiw; Jian-Guo Cui; Victor L Marcheselli; Merete Bodker; Anja Botkjaer; Katherine Gotlinger; Charles N Serhan; Nicolas G Bazan
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

4.  Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease.

Authors:  M A Bradley; W R Markesbery; M A Lovell
Journal:  Free Radic Biol Med       Date:  2010-02-18       Impact factor: 7.376

Review 5.  Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease.

Authors:  D Allan Butterfield; Miranda L Bader Lange; Rukhsana Sultana
Journal:  Biochim Biophys Acta       Date:  2010-02-20

6.  The fat-1 mouse has brain docosahexaenoic acid levels achievable through fish oil feeding.

Authors:  Sarah K Orr; Jasmin Y M Tong; Jing X Kang; David W L Ma; Richard P Bazinet
Journal:  Neurochem Res       Date:  2010-02-23       Impact factor: 3.996

7.  Promotion of oxidative lipid membrane damage by amyloid beta proteins.

Authors:  Ian V J Murray; Michael E Sindoni; Paul H Axelsen
Journal:  Biochemistry       Date:  2005-09-20       Impact factor: 3.162

8.  Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.

Authors:  Joseph F Quinn; Rema Raman; Ronald G Thomas; Karin Yurko-Mauro; Edward B Nelson; Christopher Van Dyck; James E Galvin; Jennifer Emond; Clifford R Jack; Michael Weiner; Lynne Shinto; Paul S Aisen
Journal:  JAMA       Date:  2010-11-03       Impact factor: 56.272

Review 9.  Nutritional Lipidomics in Alzheimer's Disease.

Authors:  Efstathia Kalli
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

10.  Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease.

Authors:  Thomas Fraser; Hannah Tayler; Seth Love
Journal:  Neurochem Res       Date:  2009-11-11       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.